I
t has been shown that eicosanoids, including leukotrienes (LT) and PGs, have crucial roles in the pathogenesis of airway inflammation (1) (2) (3) (4) . These eicosanoids are 5-lipoxygenase and cyclooxygenase metabolites of arachidonic acids, and the cellular availability of arachidonic acid is tightly controlled by hydrolysis of membrane phospholipids via the catalytic activity of phospholipases A 2 (PLA 2 ) (5-10). Previous animal and human studies showed that PLA 2 is involved in the genesis of airway inflammation through proinflammatory eicosanoids (11) (12) (13) (14) (15) .
A number of PLA 2 subtypes have been identified and classified into different families based on their biochemical features and primary structures (5) (6) (7) (8) (9) (10) 16) . Mammalian PLA 2 enzymes are classified into three main categories: intracellular cytosolic PLA 2 (cPLA 2 ), Ca 2+ -independent PLA 2 (iPLA 2 ), and secretory PLA 2 (sPLA 2 ), comprising 6 cPLA 2 , 9 iPLA 2 and 11 sPLA 2 (5) (6) (7) (8) (9) (10) 16) . sPLA 2 possess several characteristic features, including a low molecular mass (typically, 13-18 kDa) and an absolute catalytic requirement for millimolar concentrations of Ca 2+ (5) (6) (7) (8) (9) (10) 16) .
Two decades ago, a cell surface receptor for sPLA 2 -IB (phospholipase A 2 receptor 1; PLA 2 R) was discovered (17) . PLA 2 R, a so-called M-type PLA 2 receptor, is a type I transmembrane glycoprotein with a molecular mass of 180 kDa and is composed of a large extracellular portion consisting of an N-terminal cysteine-rich region, a fibronectin-like type II domain, a tandem repeat of eight carbohydrate-recognition domains (CRDs) and, a short intracellular C-terminal region (10, 16, 18, 19) . Three of the CRD-like domains (CRDs 3 to 5) are responsible for sPLA 2 binding (10, 16, 18, 19) . Among sPLA 2 isozymes, mouse PLA 2 R has a high affinity to sPLA 2 -IB, -IIA, -IIE, -IIF, and -X (18, 19) . The intracellular C-terminal region contains a consensus sequence motif of coated pit-mediated-endocytosis that was originally identified in the low-density lipoprotein receptor (18) (19) (20) (21) . Previous in vitro studies have demonstrated that sPLA 2 -IB and sPLA 2 -X are internalized and degraded via the lysosomal pathway after their binding to PLA 2 R, implicating a possible role of the receptor in the clearance of extracellular sPLA 2 (18) (19) (20) (21) (22) . sPLA 2 -IB and sPLA 2 -X are expressed in the lung (11, 12, 23) . The animal study using sPLA 2 -X-deficient mice showed that sPLA 2 -X produced proinflammatory eicosanoids and Th2 cytokines and played a critical role in genesis of allergen-induced airway inflammation (12) . The human study indicated that sPLA 2 -X could have a role in the generation of proinflammatory eicosanoids in the airways, leading to the development of bronchial hyperresponsiveness (11) . In addition, sPLA 2 -IB was found to elicit the production of proinflammatory eicosanoids in the lung and the contraction of airway smooth muscles (24) . PLA 2 R is highly expressed in the lung, kidney, and spleen (10, 18, 25) ; however, the possible pathologic roles of PLA 2 R remain largely unknown in these organs. Therefore, this study examined the pathogenic role of PLA 2 R in OVA-induced airway inflammation using PLA 2 R-deficient mice.
Materials and Methods

Materials
Rat monoclonal anti-PLA 2 R Ab was prepared as described in a previous report (25) . Rabbit polyclonal anti-smooth muscle a-actin (aSMA) Ab and rabbit polyclonal anti-cytokeratin Ab were purchased from Abcam (Cambridge, U.K.). Recombinant mouse sPLA 2 -X was prepared as described previously (22) . Recombinant human sPLA 2 -IB was obtained from R&D systems (Minneapolis, MN). Sodium [ 125 I] iodine (carrier-free, 3.7 GBq/ml) was purchased from Perkin Elmer (Boston, MA). ELISA kits for determination of IL-4 and IL-5 levels were obtained from R&D systems; the ELISA kit for IFN-g was obtained from Raybiotech (Norcross, GA); the ELISA kits for LTB 4 , cysteinyl leukotrienes (CysLTs), PGD 2 , and PGE 2 were obtained from Cayman Chemical (Ann Arbor, MI); the ELISA kit for 15-deoxy-D 12, 14 -PGJ 2 (15d-PGJ 2 ) was obtained from Enzo Life Science (Farmingdale, NY); and ELISA kits for sPLA 2 -IB and sPLA 2 -X were obtained from Cusabio Biotech (Wuhan, China). Cell culture reagents were obtained from Sigma-Aldrich (Tokyo, Japan) and Invitrogen (Carlsbad, CA). Other chemicals were purchased from Sigma-Aldrich unless indicated otherwise.
Mice
The experimental protocol was approved by the University of Yamanashi Animal Care and Use Committee (approval reference no. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (8th Edition, 2011). Details regarding the generation and characterization of PLA 2 R 2/2 mice (systemically deficient in PLA 2 R) were described previously (25, 26) . PLA 2 R 2/2 female mice with a C57BL/6J background from F12 to 15 (6-8 wk old, 14 to 18 g) were used in the current study. The littermates of the wild-type (PLA 2 R +/+ ) females served as a control group.
Induction of allergic airway inflammation with OVA treatment
Mice were treated with i.p. injection of 10 mg of chicken egg OVA (SigmaAldrich) and 1.125 mg of adjuvant aluminum potassium sulfate (SigmaAldrich) emulsified in 0.2 ml of sterile saline at days 0, 7, and 14. On days 21 to 23, mice were treated with intranasal administration of 50 mg of OVA in 0.05 ml saline after anesthesia with i.p. injection of 130 mg/kg ketamine and 8.8 mg/kg xylazine. Control groups were treated with saline instead of OVA, otherwise similar to that described above. On day 24, the mice were euthanized by cutting the left renal artery after anesthesia with i.p. injection of 130 mg/kg ketamine and 8.8 mg/kg xylazine. Immediately after death, the lungs were lavaged for the experiments for assays of bronchoalveolar lavage fluid (BALF). Thereafter, the lungs were removed for histological analysis. In another set of experiments, the lungs were removed immediately after the euthanasia for biochemical analysis. In some mice, citrated blood was obtained by intracardiac puncture under the anesthesia.
Bronchoalveolar lavage (BAL)
The trachea was exposed and catheterized with a 24-gauge polypropylene endotracheal tube. The lungs were lavaged 8 times with 0.5 ml of PBS to provide 4.0 ml of BALF (23) . The BALF was collected by gentle aspiration. For each animal, 90% (3.6 ml) of the total injected volume was consistently recovered. The collected BALF was combined and cooled to 4˚C. The BALF was centrifuged at 300 3 g for 10 min, and the nuclear cell count was determined using a hemocytometer. Differential cell counts were made after cytospin centrifugation and staining with Diff-Quick. A total of 500 nuclear cells were counted under oil immersion microscopy using standard morphologic criteria (assessed by size, nucleus, and chromatin). Supernatants were stored at 280˚C until assayed.
Lung histology
The trachea was exposed and catheterized as described before. Next, paraformaldehyde (4%) in PBS was instilled into the lung via the endotracheal tube with the use of a syringe at low pressure. Upper and lower lobes of the left lung were removed and fixed for 24 h in 4% paraformaldehyde. The tissues were embedded in paraffin, cut in 7-mm sections, and placed on slides. Histologic examination of the lung was determined by staining with H&E and periodic acid-Schiff (PAS). Peribronchial infiltration of inflammatory cells was graded on a semiquantitative scale, from 0 to 4; grade 0 was designated as no detectable inflammation; grade 1 was given when the bronchus was surrounded by a few inflammatory cells; grade 2 was assigned when the bronchus was surrounded by a layer one cell deep; grade 3 was given when the bronchus was surrounded by a layer two to four cells deep; grade 4 was assigned when the bronchus was surrounded by a layer more than four cells deep. The number of PASpositive mucus-containing cells was determined as the percentage of total airway epithelial cells in each airway examined. For lung morphometry, five airways per section were randomly selected from five sections (from two upper lobes and three lower lobes) per mouse and examined at a magnification of 3400. Each mouse had a score determined by the mean of the individual scores of 25 airways. These histologic measurements were conducted by two investigators (H.M., K.W.) who were blinded to the study protocol for the mice. The interobserver and intraobserver variabilities for repeated measurements of 25 airways were 3.9 6 0.4% and 4.4 6 0.5%, respectively, for the grading of peribronchial infiltration of inflammatory cells and 2.6 6 0.3% and 3.2 6 0.4%, respectively, for the percentage of PAS-positive mucus-containing cells, indicating high reproducibility in both measurements.
Immunostaining of lungs and cultured cells
The lung was instilled with 50% OCT (Tissue-Tek; Sakura Finetek, Tokyo, Japan) in PBS through the endotracheal tube. Thereafter, lungs were harvested, immediately embedded in OCT, frozen, cut into 5-mm sections and postfixed in acetone. For immunostaining, endogenous peroxidase was inactivated by incubating with 0.3% hydrogen peroxide for 30 min. After washing, the sections were blocked with 10% BSA, and then incubated with the primary Ab followed by a peroxidase-conjugated secondary Ab (Histofine Simple Stain; Nichirei Bioscience, Tokyo, Japan). To develop the brown coloration, the sections were treated with 39-diaminobenzidine tetrahydrochloride, a peroxidase substrate (Vector Laboratories, Burlingame, CA) and counterstained with hematoxylin. The primary Abs included a rat monoclonal anti-PLA 2 R Ab (25), a rabbit polyclonal antiaSMA Ab, and a rabbit polyclonal anti-cytokeratin Ab. Some sections were incubated with normal rabbit, mouse, or goat IgG instead of primary Ab as negative controls. For double immunofluorescence staining of the lung, the sections were incubated with the indicated primary Abs followed by a secondary Ab with Alexa Fluor 488 or Alexa Fluor 647 (Invitrogen, Carlsbad, CA) (23) .
Cultures of airway smooth muscle (ASM) cells (see below) in eight-well chamber slides were washed with PBS and fixed with methanol for 10 min at 220˚C. Next, the cultured cells were stained as described above. Nuclei were stained with DAPI (Vector Laboratories). Images were acquired with an Olympus FluoView 1000 confocal microscope (Olympus, Tokyo, Japan) and processed using FV10-ASW software version 1.0 (Olympus).
In vivo clearance of sPLA 2 from the lungs Iodination of sPLA 2 -IB was performed with PD-10 columns (GE Healthcare, Amersham, U.K.) (25) , yielding a specific radioactivity of 500 cpm/fmol. After anesthesia by i.p. injection of 130 mg/kg ketamine and 8.8 mg/kg xylazine, the trachea was exposed and catheterized with a polypropylene 24-gauge endotracheal tube. [ 125 I]-Labeled sPLA 2 -IB (150 ng) was instilled into the lung through the endotracheal tube. After the tracheal instillation, the cervical incision was closed with a 5-0 silk suture, and the mice were returned to their cages. All treated mice recovered rapidly after surgery. After anesthesia with ketamine and xylazine as described earlier, the lungs were lavaged to collect BALF 5, 30, or 60 min or 2 and 4 h after the instillation. BALF was spun at 300 3 g to pellet cells, and the radioactivity in the cell-free supernatant of the BALF was measured with a g counter (AccuFLEX g7000; Aloka, Tokyo, Japan). The cell-free supernatant of the BALF harvested 4 h after instillation was precipitated with 10% trichloroacetic acid (TCA), and the TCA-soluble radioactivity was measured.
Assays of cytokines, eicosanoids, and sPLA 2 The concentrations of IL-4, IL-5, IFN-g, LTB 4 , CysLTs, PGD 2 , sPLA 2 -IB, and sPLA 2 -X in BALF were measured using ELISA kits according to the manufacturer's instructions. The plasma concentrations of sPLA 2 -IB and sPLA 2 -X were also measured. The enzymatic activity of sPLA 2 in the culture medium was assayed using the sPLA 2 Assay Kit (Cayman Chemical) exactly as recommended by the manufacturer. The eicosanoid levels in the culture medium of ASM cells and A549 cells (DS Pharma Biomedical, Osaka, Japan), a cell line of human alveolar basal epithelial cells, after incubation with or without sPLA 2 -IB were measured using ELISA kits. Expression levels of mRNA of cytokines in cultures of ASM cells and A549 cells were measured with real-time PCR.
Real-time PCR
Total RNA was extracted from the lungs or cultures of cells with a Qiagen RNeasy kit and DNase I (Qiagen, Hilden, Germany). The mRNA expression levels were quantified with a two-step real-time PCR assay using SYBR Green I chemistry and a 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). The PCR primers are listed in Supplemental  Table I . The GAPDH housekeeping gene was used to normalize gene expression.
Cultures of bone marrow-derived mast cells, Th2 cells, and ASM cells
Bone marrow-derived mast cells (BMMCs) were obtained by cultivation of bone marrow cells in RPMI 1640 medium containing IL-3 (5 ng/ml; Peprotech, Rocky Hill, NJ) and 10% FBS (27) . After 3 wk, staining with May-Giemsa and toluidine blue showed that .95% of the cells were BMMCs. Th2 cells were generated from CD4 + T cells (3). CD4 + T cells were isolated using MACS (Miltenyi Biotec, Bergish Gladbach, Germany) from spleen cells and activated by plating on T cell Activation Plates (BD Biosciences, San Jose, CA) in RPMI 1640 containing IL-2 (20 ng/ml), IL-4 (20 ng/ml; PeproTech), and anti-INF-g Ab (10 mg/ml; Abcam). After 6 d of culture, Th2 cells were isolated by positive selection using a mouse IL-4 Secretion Assay (Miltenyi Biotec). ASM cells were cultured from explants of tracheas. The entire tracheas were removed, and the tracheal segments were split longitudinally and dissected into 2-3-mm squares. All segments were placed in a sterile Petri dish with DMEM containing 10% FBS and 100 mg/ml penicillin/streptomycin. The explants were incubated in a 5% CO 2 chamber at 37˚C. Explanted tracheas were removed when the outgrowing cells became locally confluent. Once the dish became confluent, the cells were passaged. All examinations were performed on confluent cells at matched passage numbers (3 to 6). The immunohistochemical analysis showed that .95% of these cells were aSMA-positive cells.
Production of PGD 2 and Th2 cytokines in cultures of BMMCs and Th2 cells
This study examined whether the constituent cells of the inflamed lung were capable of producing PGD 2 and Th2 cytokines in response to sPLA 2 -IB. BMMCs were stimulated with sPLA 2 -IB. After 30 min, the levels of PGD 2 in the culture medium were measured using ELISA kits (Cayman Chemical). Th2 cells were stimulated by various concentration of PGD 2 . After 4 h, the levels of IL-4 and IL-5 in the culture medium were measured using ELISA kits (R&D Systems).
Internalization and degradation of sPLA 2 -IB in cultured ASM cells
Cultures of ASM cells on 24-well culture plates were incubated for 2.5 h at 37˚C with 5 nM [
125 I]-labeled sPLA 2 -IB in binding medium (HBSS containing 0.1% BSA) in the absence or presence of a 50-fold excess of unlabeled sPLA 2 -IB (22) . The supernatants were removed, and the cells were treated with an acidic buffer (50 mM glycine, 0.1 M NaCl, pH 3.0) for 10 min at 4˚C. After washing with PBS, the cells' associated radioactivity was measured after solubilization of the cells with 1 N NaOH by a g counter. For the assessment of sPLA 2 -IB degradation, the cells were incubated with 5 nM [
125 I]-labeled sPLA 2 -IB for 2.5 h at 4˚C, washed with PBS, resuspended in binding medium, and incubated for the indicated times at 37˚C (22) . At the end of incubation, the supernatants were removed and precipitated with 10% TCA, and the TCA-soluble radioactivity was measured with a g counter. To examine the effects of PLA 2 R on the enzymatic activity of sPLA 2 added to the culture medium, ASM cells in 24-well culture plates were incubated with mouse sPLA 2 -X (3 mg/ml) (22) at 37˚C for the indicated times. After incubation, the supernatant was collected by centrifugation of the culture medium at 1000 3 g for 5 min at 4˚C, and the enzymatic activity of sPLA 2 -X in the supernatant was measured. Among sPLA 2 isozymes with a high affinity for PLA 2 R, sPLA 2 -X was selected because of its potent enzymatic activity (6) .
Statistical analysis
Unless otherwise stated, all data are expressed as means 6 SE. Statistical comparisons of responses were performed using Student t test. When more than two groups were compared, a one-way ANOVA was performed followed by a Sheffe test for post hoc comparison of group means. The serial changes were compared between two genotyped mice using two-way ANOVA for repeated measures followed by post hoc testing with a Scheffe test. The results were accepted as significantly different when p , 0.05.
Results
Histologic analysis of OVA-induced airway inflammation
Compared with saline-treated mice, both PLA 2 R 2/2 and wild-type (PLA 2 R +/+ ) mice after OVA treatment showed an infiltration of inflammatory cells around the airways and blood vessels and hypersecretion of mucous in the airways (Fig. 1A) . These histologic changes in the lung after OVA treatment were greater in PLA 2 R 2/2 mice than in PLA 2 R +/+ mice (Fig. 1B, 1C) .
Expression of PLA 2 R in PLA 2 R +/+ lung
In PLA 2 R +/+ mice, the immunohistochemical analysis revealed strong immunoreactivity of PLA 2 R in the circumference of airway and faintly in the alveolar wall in the lung after OVA treatment ( Fig. 2A-D) . The negative control staining had no immunoreactivity to PLA 2 R (data not shown). Confocal immunofluorescence microscopy showed that PLA 2 R immunoreactivity was colocalized in airway smooth muscle expressing aSMA and in alveolar epithelial cells expressing cytokeratin in PLA 2 R +/+ lung (Fig. 2E-L) .
Comparison of mRNA expression levels of PLA 2 R and sPLA 2 in the lungs and the number of inflammatory cells and levels of sPLA 2 , eicosanoids, and Th2 cytokines in BALF after treatment with saline or OVA between PLA 2 R +/+ and PLA 2 R 2/2 mice
In PLA 2 R +/+ mice, mRNA levels of PLA 2 R in lung tissue were not changed significantly after OVA treatment compared with saline treatment (Fig. 3A ). There were no significant differences in the mRNA expression levels of sPLA 2 -IB, -IIE, and -X in lung tissue after OVA treatment between the two genotyped mice (Fig. 3B-D) . sPLA 2 -IIF expression was not detectable in OVA-treated lung in the two genotyped mice (data not shown). Compared with saline treatment, BALF after OVA treatment showed an increase in the number of eosinophils, neutrophils, and lymphocytes, the levels of sPLA 2 -IB and -X, eicosanoids (LTB 4 , CysLTs, and PGD 2 ), Th2 cytokines (IL-4 and IL-5) in both PLA 2 R 2/2 and PLA 2 R +/+ mice ( Fig. 3E-N) . These increased levels in BALF after OVA treatment were greater in PLA 2 R 2/2 lungs than in PLA 2 R +/+ lungs ( Fig. 3E-N) . IFN-g levels in BALF were not changed significantly after OVA treatment, and the IFN-g levels were similar between PLA 2 R 2/2 mice and PLA 2 R +/+ mice after treatment with saline or OVA (Fig. 3O) . There was no detectable plasma levels of sPLA 2 -IB and -X in both PLA 2 R 2/2 and PLA 2 R +/+ mice after treatment with either saline or OVA (data not shown).
In vivo clearance of sPLA 2 -IB instilled into the lungs
To determine the in vivo kinetics of sPLA 2 (Fig. 4D) . The residual enzymatic activity of sPLA 2 -X exogenously added to the culture medium gradually decreased in cultures of ASM cells from PLA 2 R +/+ lung, whereas the sPLA 2 -X activity was barely changed in those from PLA 2 R 2/2 lung (Fig. 4E) . 
Production of PGD 2 and Th2 cytokines in BMMCs and Th2 cells
This study examined whether the constituent cells of the inflamed lung were capable of producing PGD 2 and Th2 cytokines in response to sPLA 2 -IB. The addition of sPLA 2 -IB significantly increased PGD 2 levels in the culture medium of BMMCs (Fig. 5A ). The addition of PGD 2 to Th2 cells significantly increased levels of Th2 cytokines IL-4 and IL-5 levels in the culture medium (Fig. 5B) .
Production of eicosanoids and cytokines in cultures of ASM cells and A549 cells in response to sPLA 2 -IB
This study examined whether there is a difference in production of anti-inflammatory or proinflammatory eicosanoids and cytokines in response to sPLA 2 -IB in ASM cells through PLA 2 R-mediated mechanisms. Among eicosanoids and cytokines that we examined (28), there was not significant increase in their levels in ASM cells from either PLA 2 R 2/2 mice or PLA 2 R +/+ mice (Supplemental Figs. 1A, 2A), except that levels of PGD 2 and PGE 2 increased at 100 nM of human sPLA 2 -IB in culture of ASM cells from PLA 2 R 2/2 mice (Supplemental Fig. 1A ). The levels of PGD 2 and PGE 2 in the culture medium of ASM cells from PLA 2 R 2/2 mice did not change in response to the same dose of catalytically inactive human sPLA 2 -IB pretreated for 4 h with bromophenylacylbromide (1 mM; Sigma-Aldrich), a blocker of sPLA 2 -IB activity (Supplemental Fig. 1B) . Similarly, sPLA 2 -IB did not induce either eicosanoid or cytokine levels in cultures of A549 cells, a cell line of human alveolar basal epithelial cells that express PLA 2 R (Supplemental Fig. 1C and Fig. 2B ).
Discussion
This study demonstrated that the OVA-induced airway inflammation, characterized by more eosinophils and neutrophils in The Journal of ImmunologyBALF and inflammatory histologic changes in the airway, was stronger in PLA 2 R 2/2 mice than in PLA 2 R +/+ mice. PLA 2 R 2/2 mice had higher levels of sPLA 2 -IB and sPLA 2 -X in BALF after OVA treatment than did PLA 2 R +/+ mice. These higher levels were associated with greater levels of eicosanoids and Th2 cytokines in BALF from PLA 2 R 2/2 mice than from PLA 2 R +/+ mice. Previous animal and human studies showed that sPLA 2 have an important role in the genesis of airway inflammation through the production of proinflammatory eicosanoids in a variety of inflammatory cells (11) (12) (13) (14) (15) . Eicosanoids including CysLTs, LTB 4 , and PGD 2 cause lung inflammation directly or indirectly through induction of Th2 cytokines (1) (2) (3) (4) . In line with these previous reports, the present in vitro study showed that sPLA 2 -IB increased PGD 2 in mast cells and that PGD 2 induced Th2 cytokines (IL-4 and IL-5) in Th2 cells. Together, the results suggest that the greater increase in sPLA 2 -IB and sPLA 2 -X levels can result in higher levels of proinflammatory eicosanoids and Th2 cytokines, leading to enhanced inflammation in the airway after OVA treatment in PLA 2 R 2/2 mice compared with PLA 2 R +/+ mice. In agreement with previous reports (10, 18, 19, 21, 22) , the current study showed that cultures of ASM cells, expressing PLA 2 R, internalized and degraded sPLA 2 -IB. After the exogenous addition of sPLA 2 -X, the residual enzymatic activity of sPLA 2 -X decreased more slowly in the culture medium of ASM cells from PLA 2 R 2/2 mice than PLA 2 R +/+ mice. In line with these in vitro studies, the present in vivo experiments showed that intratracheally instilled sPLA 2 -IB decreased much more slowly in BALF of PLA 2 R 2/2 mice than that of PLA 2 R +/+ mice. In addition, after the instillation of [
125 I]-labeled sPLA 2 -IB, TCA-soluble radioactivity in BALF was lower in PLA 2 R 2/2 lungs than PLA 2 R +/+ lungs, indicating lower rates of degradation of sPLA 2 -IB in PLA 2 R 2/2 lung than PLA 2 R +/+ lung. These data suggested that PLA 2 R played a role in the clearance of sPLA 2 from the lung and that a deficiency of PLA 2 R resulted in the increase in sPLA 2 levels through impaired clearance of sPLA 2 . That result in turn appears to have led to exacerbation of sPLA 2 -mediated inflammation of the airway in PLA 2 R 2/2 mice. This scenario needs to be confirmed by additional experiments examining whether the increase in the OVA-induced inflammation of lung can be reversed by reexpression of PLA 2 R in a PLA 2 R 2/2 lung.
Mouse PLA 2 R has a high affinity for sPLA 2 -IB, -IIA, -IIE, -IIF, and -X (18, 19, 22) . A previous report showed that sPLA 2 -IB and sPLA 2 -X are expressed in the bronchial epithelium and alveolar epithelial cells or infiltrated inflammatory cells (23) . The increase in lung expression of sPLA 2 -IB and sPLA 2 -X mRNAs after OVA treatment was similar in PLA 2 R +/+ and PLA 2 R 2/2 mice. Thus, in the two genotypes, there might not be a difference in the production of these sPLA 2 in OVA-treated lung. The low clearance of sPLA 2 (rather than an increase in their production) could partly account for relatively higher levels of these sPLA 2 in BALF of PLA 2 R 2/2 mice compared with those of PLA 2 R +/+ . It was unlikely that levels of sPLA 2 -IB and sPLA 2 -X in BALF were derived from plasma because their levels were not detectable in plasma in both genotyped mice after treatment with either saline or OVA. sPLA 2 -IIE is expressed in lung alveolar cells as reported previously (29) . Although lung expression of sPLA 2 -IIE was weak in the current study, we cannot rule out the possibility that sPLA 2 -IIE has a role in the increase in OVA-mediated inflammation in the lungs of PLA 2 R +/+ mice. sPLA 2 -IIF was not detectable in OVAtreated lungs. sPLA 2 -IIA is naturally disrupted by a frameshift mutation in C57BL/6J background mice (30) . Thus, sPLA 2 -IIA and IIF were unlikely to contribute to the difference in the lung inflammation between the two genotypes.
Although the present and previous in vitro experiments using cultured cells indicated that PLA 2 R internalizes and degrades sPLA 2 (22) , a previous in vivo experiment failed to show the clearance effect of PLA 2 R on sPLA 2 -IB in systemic circulation (26) . In this regard, the current study clearly showed that PLA 2 R acted as a sink for sPLA 2 in the lung and that PLA 2 R might protect against sPLA 2 -mediated airway inflammation through clearance of sPLA 2 in vivo. Moreover, it is known that PLA 2 R is expressed in a variety of cells and organs, including the kidney (10, 18, 25, 31) . It remains to be determined whether PLA 2 R also functions as a clearance receptor for sPLA 2 and blocks the biologic effects in these tissues. We previously discovered a soluble form of PLA 2 R that is derived from membrane-bound PLA 2 R by protease cleavage (18, 32) . Soluble PLA 2 R retains all the extracellular domains of the membrane-bound receptor and blocks the biologic functions of sPLA 2 -IB and -X after binding (18, 32) . Therefore, it is possible that soluble PLA 2 R has an additional role in the attenuation of airway inflammation in PLA 2 R +/+ mice, although the current study did not elucidate its possible effects in lung tissue.
Previous reports raised the possibility that the cytoplasmic tail of PLA 2 R is directly linked to a signal transduction system that induces cell proliferation, eicosanoid production, and inflammation independent of intrinsic enzymatic activities of sPLA 2 (15, 33, 34) . We and others showed that some sPLA 2 act in concert with cPLA 2 a to induce eicosanoid generation (35, 36) , and PLA 2 R-mediated intracellular transduction signals can participate in the cross talk between sPLA 2 -IB and cPLA 2 a (37). However, the current study did not find any evidence that eicosanoids and cytokines were produced in response to sPLA 2 -IB in ASM cells through PLA 2 R-mediated mechanisms. We cannot rule out the possible effects of a putative signal transduction system on the present findings in PLA 2 R +/+ mice; however, the cytoplasmic tail of PLA 2 R does not seem to transduce any specific signals other than internalization signals on the basis of its sequence (18) (19) (20) (21) ). The precise mechanisms by which PLA 2 R inhibited lung inflammation are still unclear. It remains undefined whether PLA 2 R acts solely as a sink of sPLA 2 and whether PLA 2 R can directly transduce specific intracellular signals that lead to production of anti-inflammatory molecules or suppression of the production of proinflammatory molecules.
In conclusion, in a mouse model of OVA-mediated lung inflammation, PLA 2 R deficiency increased sPLA 2 -IB and sPLA 2 -X levels in the lung through their impaired clearance from the lung, leading to exaggeration of lung inflammation. PLA 2 R might play a protective role in the pathogenesis of lung inflammation.
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